BOLAGO88: Agen Judi Slot Online Gacor Gampang Menang Hari Ini
BOLAGO88: Situs Slot303 Online Gacor Resmi Gampang Maxwin
SPORT77: Daftar Situs Slot Online Terpercaya Bet88 Gacor Hari Ini
Clubjudi: Daftar Situs Slot Online Gacor Terbaru | Agen Slot Online Terpercaya 2025
Clubjudi: Daftar Situs Slot Gacor Terpercaya dan Terbaik 2025
The current Board of Directors, appointed by the Shareholders at the Annual General Meeting on 29th April 2022, is composed of twelve members. The Board of Directors stays in charge until the Annual General Meeting for the approval of the Financial Statements as at 31st December 2024. The professional CV of each director is listed below:
The Corporate Governance and Ownership Structure Reports may be consulted for further information on the Board of Directors and, in particular, on the following: the procedures for appointing and replacing the board: its role and functioning; the executive officers and bodies: the independent directors.
On 6th May 2021, upon the proposal of the Remuneration and Nominations Committee, the Board of Directors defined the following general guidelines regarding the maximum number of offices as directors or statutory auditors in other listed companies or significantly-sized companies that can be considered compatible with an effective performance of the role of Director of Recordati S.p.A
On 28th October 2021 the Board of Directors of Recordati S.p.A. defined the following policy on qualitative and quantitative criteria for the purposes of assessing independence requirements, pursuant to recommendation 7, first period, points (c) and (d), in article 2 of the Corporate Governance Code:
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Rob Koremans, qualified as Medical Doctor from RSM Erasmus University in the Netherlands and Executive MBA in US, has over 30 years’ experience in managerial and executive roles, gained mainly in the pharmaceutical industry at various international companies.
In 1988 he started his professional career at Sanofi in the Netherlands as Product Manager, then being appointed as Head of Cardiovascular Unit.
In 1990, he joined Excerpta Medica Medical Communications, part of Elsevier Group, as International Business Development Director. After one year experience as Marketing & Service Manager at J&J Cilag International in Switzerland, in 1993 he joined Serono Group where he covered different positions with growing responsibilities: he was first General Manager at Ares-Serono in the Netherlands, then Managing Director at Serono Germany and finally Vice President Europe based in Switzerland.
In 2000, he joined Grunenthal as Head of Area Management Europe & USA and Head of Global Marketing, being then appointed Member of the Executive Board.
In 2007, he became Chief Executive Officer and co-owner at Cryo-Save Group, Europe’s leading stem cell storage company; two years later, he was appointed as President and CEO of Zentiva, part of the Sanofi-Aventis Group, in Czech Republic.
In 2012, he joined Teva Pharmaceutical Industries (TPI) as Member of TPI Executive Committee and President & CEO of Teva Pharmaceuticals Europe, then becoming President & CEO Global Specialty Medicines. Finally, in 2018 he joined Nutreco, global leader in animal nutrition, aqua culture and alternative proteins, as Chief Executive Officer.
In December 2021 he joined Recordati as Chief Executive Officer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003
The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.
In any event we assure you that your data will be processed solely for the above purposes and using the above methods.
The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.
A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).
Requests must be sent to the Data Processor of Recordati:
by email, to the address: ;
or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.
In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.
Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.